Aquestive Therapeutics (AQST)
(Real Time Quote from BATS)
$3.03 USD
+0.26 (9.39%)
Updated Jul 16, 2024 02:58 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 161 - 180 ( 402 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmission Accepted, PDUFA Set for December 23, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant New Drug Application Resubmitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmitted On Schedule, PDUFA Expected in Late 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Solid Quarter With Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; On-track to Resubmit Libervant? NDA in June
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L